Mxi1 Mutations in Human Neurofibrosarcomas

Xiao-Jin Li,1 Dong-Yu Wang,1 Yue Zhu,1, 2 Rong-Jun Guo,1 Xing-Duo Wang,2 Kaco Lubomir,1 Kiyoshi Mukai,3, 7 Hiroki Sasaki,4 Haruhiko Yoshida,5 Teruaki Oka,6 Rikuo Machinami,6 Kazuya Shinmura,1 Masamitsu Tanaka1 and Haruhiko Sugimura1, 8

1First Department of Pathology, Hamamatsu University School of Medicine, 3600 Handa-cho, Hamamatsu 431-3192, 2Department of Orthopedic Surgery, First Clinical College of China Medical University, Shenyang, 110001 China, 3Pathology Division, National Cancer Center Research Institute, East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, 4Genetics Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Tokyo 104-0045, 5Tottori University College of Medical Care Technology, 133-2 Nishi-machi, Yonago, Tottori 683-0826 and 6First Department of Pathology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033

Mxi1 is thought to negatively regulate Myc function and may therefore be a potential tumor suppressor gene. Little effort has yet been made to find alterations involving this gene in human solid tumors. We screened 31 human gastric cancers, 7 esophageal cancers, 85 bone and soft tissue tumors of various types, including 4 neurofibrosarcomas. We also examined 29 human tumor cell lines consisting of 12 esophageal cancers, 7 glioma/glioblastomas and 10 others for Mxi1 mutations in exons 1, 2, 4 (HLH domain), 5 and 6. Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and subsequent sequencing revealed three distinct polymorphisms in the intron-exon boundary upstream from exon 6. We discovered a missense mutation, GCA to GTA (Ala 54 Val), in exon 2 in a neurofibrosarcoma patient (case 1), two missense mutations, AAA to CAA (Lys 118 Gln) and GAA to GGA (Glu 154 Gly) in exon 5 of another neurofibrosarcoma patient (case 2), and 3 amino acid substitutions, GTG to GCG (Val 179 Ala), GTT to GCT (Val 181 Ala) and TTC to CTC (Phe 186 Leu), in a third neurofibrosarcoma patient (case 3). In case 3, loss of heterozygosity was also demonstrated by informative (TTC)3/(TTC)2 polymorphism. Our data demonstrate that mutations occur in the Mxi1 gene in neurofibrosarcoma. Missense mutations in the functional domain of Mxi1 in these cases may be involved in the pathogenesis of neurofibrosarcoma.

Key words: Mxi1 — Neurofibrosarcoma — NF1 — c-myc — Mutation

Mxi1 antagonizes the functions of Myc by heterodimerizing with Max to compete with Myc for limited amounts of Max1) or with Myc/Max for the Myc/Max consensus recognition sequence, CACGTG.2) The Mxi1 gene has been mapped to chromosome 10, band q24-q25,3, 4) a region which shows frequent translocations, deletions, or rearrangements in a number of human tumors.5, 6) Induction of Mxi1 expression in U87MG, a glioblastoma cell line lacking endogenous Mxi1 expression, resulted in a decreased U87MG growth rate.7) In another study, overexpression of Mxi1 dose-dependently inhibited the expression of ornithine decarboxylase, which is believed to be a Myc target gene, both in vivo and in vitro.2) The loss of Mxi1 function is known to be associated with human glioblastoma development.7) Mxi1 knockout mice exhibit progressive, multisystem abnormalities and increased susceptibility to tumorigenesis in response to carcinogen exposure and also in the case of Ink4a deficiency.8) Despite the accumulating evidence indicating that Mxi1 plays a tumor suppressor gene role, to date, only a few studies of prostate cancer have demonstrated the Mxi1 gene to be mutated or deleted.9, 10) Recently we demonstrated Mxi1 alterations to be relatively common in esophageal squamous cancer cells from experimentally induced rodent tumors (Wang et al., personal communications). Herein, we extended our search for Mxi1 mutations to 31 human gastric cancers, 7 esophageal cancers and 85 bone and soft tissue tumors of various types including 4 neurofibrosarcomas. We also examined 29 human tumor cell lines derived from 12 esophageal cancers, 7 glioma/glioblastomas and 10 other tumors.

MATERIALS AND METHODS

Samples Specimens of 31 spontaneous gastric cancers, 7 esophageal cancers, and 85 bone and soft tissue tumors of various types, including 4 neurofibrosarcomas, 7 osteosarcomas, one fibrosarcoma, 8 chondrosarcomas, 4 malignant fibrous histiocytomas, 3 synovial sarcomas, 3 rhabdomyo-
K (0.04 mg/ml) and incubated at 37 °C overnight. The suspension was then heated at 65 °C for 7 min to inactivate the proteinase K, and finally centrifuged for 10 min. The supernatant was used as the DNA template in the subsequent polymerase chain reaction (PCR) amplifications.

Loss of heterozygosity (LOH) detection  TG repeats in intron 3 and AAAAC repeats in the 3′ non-coding region

Table I. Primers for PCR

| Exon | Forward | Reverse |
|------|---------|---------|
| 1    | 5′-ATGGAGCGGGTGAAGATGAT-3′ | 5′-GCACTGCCGAAAAGATTAG-3′ |
| 2    | 5′-GGTCAATGGATTGGTGTCAC-3′ | 5′-TAAGGGTTCCCGCTTCTA-3′ |
| 4    | 5′-TAAAGACCGCTCTGATTGTCG-3′ | 5′-ACCAGAATCGAGGAAATTGTG-3′ |
| 5    | 5′-TGGTTTGTACTGGACTATAACAC-3′ | 5′-ATGGTTAGATTTCATTAGAAG-3′ |
| 6    | 5′-TTAGTTTTTGAAGTGCGCC-3′ | 5′-TTATGTCATGCGGGTGTC-3′ |

PCR, single-strand conformation polymorphism (SSCP) and sequencing  We designed primers for amplification of exons 1, 2, 4, 5 and 6 of human Mxi1 by using flanking intronic sequences (Table I). A 100 ng DNA sample was diluted into a 24 µl reaction solution containing 10 mM Tris-HCl (pH 8.5), 50 mM potassium chloride, 1.5 mM magnesium chloride, 0.2 mM of each deoxyribonucleoside triphosphate, 0.5 µM of each primer, and 1 unit Taq polymerase (Boehringer Mannheim, Mannheim, Germany). PCR was performed in a Progra Tem PC-700 (Astec, Tokyo). After an initial denaturation at 95 °C for 5 min, the DNA was amplified in 30 cycles of 30 s at 95 °C, 60 s at 55 °C, and 60 s at 72 °C, followed by a final extension step of 10 min at 72°C.

We added 5 µl of loading buffer (95% formamide and dye) to 5 µl of the PCR product, which was then denatured for 15 min at 96°C and loaded on 10% nondenaturing polyacrylamide gel with or without 5% glycerol at room temperature and 4°C. SSCP gels were stained with a silver staining kit (Wako, Osaka). Because PCR is notoriously error-prone and can introduce mutations with a frequency of approximately 8.0 × 10−6 per base pair per duplication of Taq DNA polymerase,12) we independently repeated the PCR-SSCP three additional times on each sample that had an extra band on SSCP to rule out artificially introduced mutation. We also used Pfu DNA polymerase (Stratagene, La Jolla, CA) which introduces mutations at a rate of 1.3 × 10−6 per base pair per duplication in cases showing a suspected mutation.12)

PCR fragments from the cases in which we found an extra band on SSCP, were cloned into pBS (Stratagene) after treatment with polynucleotide kinase or pGEM-T EasyVector (Promega, Madison, WI). Six clones were sequenced with Sequenase Version 2.0 (Amersham, Cleveland, OH), such that at least two clones exhibited the same sequence consistently. We also directly sequenced exon 6 of neurofibrosarcoma case 3 employing an “ABI PRISM” Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA) and an ABI 373A DNA Sequencer (Applied Biosystems, Foster City, CA) to confirm the mutations.
of human Mxi1 were detected. We performed PCR with primers 5'-GTAACACACTGTAGGATGGC-3' and 5'-TA-AAAACACAGCGAGAAGGA-3' for TG repeats, 5'-GG-TTACTCCAGTGCCAGTGT-3' and 5'-TTAAATACAGGTCCTCTGACCC-3' for AAAAC repeats, to detect LOH in 31 gastric cancers, 7 esophageal cancers and 4 neurofibrosarcomas.

**Polymorphism** We first noticed (TTC)$_3$ in place of the (TTC)$_2$ in GenBank (U32515) in some of the tumors in our series. To determine whether or not this is a polymorphism, we surveyed peripheral blood DNAs of several populations. Peripheral blood DNA was extracted as described previously.\(^{13}\) The primers used for detecting (TTC)$_3$/(TTC)$_2$ were 5'-GTTAGTTTTTGAAGGTGCGC-3' and 5'-TGTTATGTCATGCTGGGTTC-3'.

**RESULTS**

We found an extra SSCP band in exon 6 in one case of chondrosarcoma. We also discovered extra SSCP bands in exon 2 in neurofibrosarcoma case 1, in exon 5 in neurofibrosarcoma case 2 and in exon 6 in neurofibrosarcoma case 3. The extra SSCP bands detected in 320 and HT-1080 were in exon 2 and the extra SSCP bands detected in

---

**Fig. 1.** The SSCP results of neurofibrosarcoma cases 1, 2 and 3 and the sequencing results of cases 1 and 2. (A) The SSCP results of neurofibrosarcoma cases 1, 2 and 3. Arrows indicate the extra bands. (B) The sequencing results of neurofibrosarcoma case 1. There is a missense mutation, GCA to GTA (Ala to Val), at codon 54. (C) The Bsp1286I digestion results of exon 2 PCR fragments from tumor and normal tissue DNA. The normal tissue is expected to generate two bands of 44 and 65 bp by Bsp1286I digestion, in addition to a constant band of 106 bp (lanes 2, 3 and 4). The mutation at codon 54 resulted in another 109 bp, presumably undigested, band as expected (lane 1, case 1). The bands of 44 and 65 bp in lane 1 may be from contaminating normal tissue or another wild-type allele. Lanes 5, 6, 7 and 8 represent undigested PCR products. D: The sequencing results of neurofibrosarcoma case 2. The left panel shows a missense mutation, AAA to CAA (Lys to Gln), at codon 118. The right panel shows the area containing another missense mutation, GAA to GGA (Glu to Gly), at codon 154.
Mxi1 Mutations

DLD-1 and U87 were in exon 6. Fig. 1A shows the SSCP results of neurofibrosarcoma cases 1, 2 and 3. By sequencing, a (TTC)\(_3\) to (TTC)\(_2\) change was detected at the intron-exon boundary located 21 bp upstream from exon 6 in the chondrosarcoma case. In neurofibrosarcoma case 1, who had neurofibromatosis type 1 (NF1), we found one missense mutation in exon 2, GCA to GTA (Ala 54 Val) (Fig. 1B). According to the GenBank data, there are two Bsp\(_{1286}I\) recognition sites, at codons 40 and 54, in exon 2. The PCR fragments of exon 2 originating from normal and tumor DNAs were digested with Bsp\(_{1286}I\) to confirm that the normal exon 2 sequence is identical with the GenBank codon 54. As expected, the pattern shown in lane 1 confirmed the mutation in codon 54 in neurofibrosarcoma case 1 (Fig. 1C). We also used RsaI to digest the PCR fragments of exon 2 originating from normal and tumor DNAs because the mutation induced an additional RsaI recognition site, and confirmed the result obtained with Bsp\(_{1286}I\) (data not shown).

In neurofibrosarcoma case 2, who also had NF1, we detected two missense mutations in exon 5, AAA to CAA (Lys 118 Gln) and GAA to GGA (Glu 154 Gly), in the same clone (Fig. 1D). In neurofibrosarcoma case 3, we found 3 amino acid substitutions in exon 5, GTG to GCG (Val 179 Ala), GTT to GCT (Val 181 Ala) and TTC to CTC (Phe 186 Leu) (Fig. 2). In order to verify the mutations in case 3, we designed new primers, 5'-TGAAGGTGCCTATACTCGA-3' and 5'-AGGCTGCTGTGGTCATCAAT-3', for short exon 6 PCR fragments and confirmed the same base substitutions. Since the SSCP pattern contained residual wild-type allele in cases 1 and 2, some wild-type allele appears to remain in these tumors. On the other hand, no wild-type band was present in case 3, which probably reflects loss of the wild-type allele. The results of SSCP and sequencing of neurofibrosarcoma cases 1, 2 and 3 are summarized in Table II.

In exon 2 of the HT-1080, 320 cell line, we found a GGC-to-GGT alteration at codon 29. A (TTC)\(_3\) to (TTC)\(_2\) change, which is the same as in the chondrosarcoma, was detected in exon 6 in DLD-1 and U87MG.

We checked for LOH of Mxi1 using the TG repeats in intron 3 and AAAAC repeats in the 3' non-coding region, but found none in the two repeat regions of 31 gastric cancers, 7 esophageal cancers and 4 neurofibrosarcomas, which yielded corresponding normal DNA. The numbers of TG informative cases are 12, 2 and 0 for gastric cancers, esophageal cancers and neurofibrosarcomas, respectively. The numbers of AAAAC informative cases are 6, 4 and 0 for gastric cancers, esophageal cancers and neurofibrosarcomas, respectively.

As to the aforementioned alterations, (TTC)\(_3\) to (TTC)\(_2\) in intron 5 of DLD-1, U87MG and one of the chondrosarcoma cases, we could not determine whether these constituted somatic changes since there was no corresponding normal DNA in these cell lines and the sarcoma. We checked normal tissues from 50 Japanese, 50 Chinese and 44 Australian Caucasians and demonstrated 26:17:1 {((TTC)\(_3\)/(TTC)\(_2\))/((TTC)\(_3\)/(TTC)\(_2\))/(TTC)\(_2\)/(TTC)\(_2\)} in the Cau-
Caucasians, while no such alterations were present in Japanese and Chinese, suggesting the (TTC)₃/(TTC)₂ sequences are clearly a polymorphism, but that the (TTC)₂ allele is rare in Japanese and Chinese (Fig. 3). In the normal tissue from neurofibrosarcoma case 3, the (TTC)₃/(TTC)₂ type was detected, while the (TTC)₃/(TTC)₃ type was present in tumor tissue, suggesting LOH (Fig. 4). We did not find LOH in this region of neurofibrosarcoma cases 1 and 2. In order to determine whether the alteration GGC to GGT at codon 29 of exon 2 of the HT-1080, 320 cell line is a polymorphism, we examined normal tissues from 30 Japanese and 40 Australian Caucasians. As no polymorphism was detected, we assumed this to be a silent mutation.

DISCUSSION

Screening a total of 123 primary tumors and 29 cell lines revealed the Mxi1 mutation to be rare in human solid tumors, including one case of neurofibroma associated with NF1 and the neurofibroma portions of neurofibrosarcoma cases 1 and 2. The low frequency of Mxi1 alterations is consistent with previous reports on lung and prostate cancer. However, 3 of 4 neurofibrosarcomas, rare and highly malignant tumors, had mutations in functional exons. One missense mutation was detected at codon 54 in neurofibrosarcoma case 1, who had NF1. The mutation is situated between two critical regions, the Sin3-interacting domain and the basic domain. It would be intriguing to know whether this mutation influences the spatial interactions of Sin3 and Mxi1.

We found another missense mutation at codon 118 in the Zip region of neurofibrosarcoma case 2, who also had NF1. Since Mxi1 and Max dimerize through their HLH and Zip motifs to prevent the formation of Myc-Max heterodimers and compete with these heterodimers for binding to target sites, the Zip region mutation observed here probably prevents the formation of Mxi1-Max heterodimers and may thereby impair the function of Myc inhibition.

We demonstrated another missense mutation at codon 154 in neurofibrosarcoma case 2 and missense mutations in exon 6 in neurofibrosarcoma case 3. These are at the C-terminal domain of Mxi1, which was shown recently to repress the transcription from the major c-Myc promoter, P2. The repression is independent of Mxi1 binding to mSin3, but is dependent on the Mxi1 HLH domain, Zip domain and C-terminal domain. The C-terminal domain mutations observed here may thus impair the Mxi1 function. We also demonstrated LOH in neurofibrosarcoma case 3. SSCP analysis demonstrated loss of wild-type alleles in tumor DNA (Fig. 1A, case 3). A change, from “(TTC)₂-exon 6 wild type/(TTC)₃-exon 6 wild type” to “(TTC)₂-exon 6 mutation/(missing)” is assumed to have occurred in this tumor. These findings in neurofibrosarcoma case 3 may be compatible with a two-hit mechanism. Although we could not find LOH in neurofibrosarcoma cases 1 and 2, other factors, for example methylation, that can not be detected by the method used here, may be involved in inactivation of the allele.

Neurofibrosarcoma is known to develop in patients with NF1 at a reported incidence of 2–4%, but little is known about the molecular genetic alterations that underlie this malignant transformation. Our findings suggest that the Mxi1 mutation may play a role in malignant transformation of neurofibromas in NF1 patients. Neurofibromin, the product of NF1 gene, contains a GTPase-activating protein (GAP)-related domain which negatively regulates Ras activity. Ras is involved in the regulation of c-myc gene expression. Thus, multiple genes are involved in malignant transformation of neurofibroma in NF1 patients and Mxi1 may be among the candidate genes.

Although Mxi1 mutations were rare in our samples, the presence of Mxi1 mutations in neurofibrosarcoma may justify a more extensive search given the possible involvement of this gene in other tumors. The codons involved in the mutation
were conserved among human, rat, mouse and zebrafish, suggesting that they are important to the function of Mxi1. Although some of them changed only in the same neutral amino acid, these mutations were located in or near possibly functional regions, so the function of Mxi1 may be affected. Further study of these mutations, especially in patients with NF1, is warranted.

ACKNOWLEDGMENTS

We thank Dr. Nicole Schreiber-Agus and Dr. Hideyuki Saya for their insightful comments. This work was supported by

REFERENCES

1) Dooley, S., Wundrack, I., Blin, N. and Welter, C. Coexpression pattern of c-myc associated genes in a small cell lung cancer cell line with high steady state c-myc transcription. *Biochem. Biophys. Res. Commun.*, 213, 789–795 (1995).

2) Wu, S., Pena, A., Korcz, A., Soprano, D. R. and Soprano, L. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex. *Oncogene*, 12, 621–629 (1996).

3) Edelhoff, S., Ayer, D. E., Zervos, A. S., Steingrimsson, E., Jenkins, N. A., Copeland, N. G., Eisenman, R. N., Brent, R. and Disteche, C. M. Mapping of two genes encoding members of a distinct subfamily of MAX interacting proteins: MAD to human chromosome 2 and mouse chromosome 6, and MXI1 to human chromosome 10 and mouse chromosome 19. *Oncogene*, 9, 665–668 (1994).

4) Shapiro, D. N., Valentine, V., Eagle, L., Yin, X., Morris, S. W. and Prochownik, E. V. Assignment of the human MAD and MXI1 genes to chromosomes 2p12-p13 and 10q24-q25. *Genomics*, 23, 282–285 (1994).

5) Gray, I. C., Phillips, S. M., Lee, S. J., Neoptolemos, J. P., Jenkins, N. A., Copeland, N. G., Eisenman, R. N., Brent, R. and Disteche, C. M. Loss of the chromosomal region 10q23-25 in prostate cancer. *Cancer Res.*, 55, 4800–4803 (1995).

6) Albarosa, R., DiDonato, S. and Finocchiaro, G. Redefinition of the coding sequence of the MXII gene and identification of a polymorphic repeat in the 3’ non-coding region that allows the detection of loss of heterozygosity of chromosome 10q25 in glioblastomas. *Hum. Genet.*, 95, 709–711 (1995).

7) Wechsler, D. S., Shelly, C. A., Petroff, C. A. and Dang, C. V. MX11, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. *Cancer Res.*, 57, 4905–4912 (1997).

8) Schreiber-Agus, N., Meng, Y., Hoang, T., Hou, H., Jr., Chen, K., Greenberg, R., Cordon-Cardo, C., Lee, H. W. and DePinho, R. A. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. *Nature*, 393, 483–487 (1998).

9) Prochownik, E. V., Eagle Grove, L., Deubler, D., Zhu, X., L. Stephenson, R. A., Rohr, L. R., Yin, X. and Brothman, A. R. Commonly occurring loss and mutation of the MX11 gene in prostate cancer. *Genes Chromosom. Cancer*, 22, 295–304 (1998).

10) Eagle, L. R., Yin, X., Brothman, A. R., Williams, B. J., Atkin, N. B. and Prochownik, E. V. Mutation of the MX11 gene in prostate cancer. *Nat. Genet.*, 9, 249–255 (1995).

11) Sakamoto, H., Mori, M., Taira, M., Yoshida, T., Matsukawa, S., Shimizu, K., Sekiguchi, M., Terada, M. and Sugimura, T. Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. *Proc. Natl. Acad. Sci. USA*, 83, 3997–4001 (1986).

12) Cline, J., Braman, J. C. and Hogrefe, H. H. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. *Nucleic Acids Res.*, 24, 3546–3551 (1996).

13) Sambrook, J., Fritsch, E. F. and Maniatis, T. “Molecular Cloning,” pp. 9.14–9.23 (1989). Cold Spring Harbor Laboratory Press, New York.

14) Petersen, S., Wolf, G., Bockmuhl, U., Gellert, K., Dietel, M. and Petersen, I. Allelic loss on chromosome 10q in human lung cancer: association with tumor progression and metastatic phenotype. *Br. J. Cancer*, 77, 270–276 (1998).

15) Kuczyk, M. A., Serth, J., Bokemeyer, C., Schwede, J., Herrmann, R., Machtens, S., Grunewald, V., Hofner, K. and Jonas, U. The MX11 tumor suppressor gene is not mutated in primary prostate cancer. *Oncol. Rep.*, 5, 213–216 (1998).

16) Zervos, A. S., Gyuris, J. and Brent, R. Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognizing sites. *Cell*, 72, 223–232 (1993).

17) Lee, T. C. and Ziff, E. B. Mxi1 is a repressor of the c-myc promoter and reverses activation by USF. *J. Biol. Chem.*, 274, 596–606 (1999).

18) Knudson, A. G., Jr., Hethcote, H. W. and Brown, B. W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. *Proc. Natl. Acad. Sci. USA*, 72, 5116–5120 (1975).

19) Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S. and Downward, J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibro-
matosis patients. *Nature*, **356**, 713–715 (1992).

20) DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C. and Lowy, D. R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. *Cell*, **69**, 265–273 (1992).

21) Kim, H. A., Rosenbaum, T., Marchionni, M. A., Ratner, N. and DeClue, J. E. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. *Oncogene*, **11**, 325–335 (1995).

22) Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T. and Shannon, K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. *Nat. Genet.*, **12**, 144–148 (1996).

23) Kerkhoff, E., Houben, R., Loeffler, S., Troppmair, J., Lee, J. E. and Rapp, U. R. Regulation of c-myc expression by Ras/Raf signalling. *Oncogene*, **16**, 211–216 (1998).